Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 6/20 | 0.41 |
| ▸ | SI | P14410 | 2/20 | 0.40 |
| ▸ | GBA1 | P04062 | 6/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264743 | 1.00 | OGA (0.41) | OGASIGBA1MGAMPYGL | |
| SCHEMBL27788824 | 1.00 | OGA (0.41) | OGASIGBA1MGAMPYGL | |
| SCHEMBL19069765 | 0.79 | GBA1 (0.30) | GBA1 | |
| SCHEMBL13756984 | 0.78 | SI (0.50) | OGASIGBA1MGAMPYGL | |
| SCHEMBL13599731 | 0.78 | SI (0.50) | OGASIGBA1MGAMPYGL | |
| SCHEMBL16315598 | 0.78 | SI (0.50) | OGASIGBA1MGAMPYGL | |
| SCHEMBL264749 | 0.78 | SI (0.50) | OGASIGBA1MGAMPYGL | |
| SCHEMBL13172114 | 0.78 | SI (0.50) | OGASIGBA1MGAMPYGL | |
| SCHEMBL13749980 | 0.78 | SI (0.50) | OGASIGBA1MGAMPYGL | |
| SCHEMBL10186325 | 0.78 | SI (0.50) | OGASIGBA1MGAMPYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-9695154-B2 | Heteroaryl inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | OGA 1471/4885SI 2175/4885GBA1 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.